| T773 |
0-625 |
Sentence |
denotes |
Skipper, et al. (2020) [37] Randomized, double-blind, placebo-controlled trial491 symptomatic, non-hospitalized adult patients with early or mild COVID-19 HCQ group -> HCQ 800 mg once, followed by 600 mg in 6 to 8 h, then 600 mg daily for 4 more daysControl group-> masked placebo14 weeks of treatment HCQ did not reduce symptom severity when compared with placebo in non-hospitalized early/mild COVID-19 patients (difference in symptom severity: relative, 12%; absolute, −0.27 points (95% CI, −0.61 to 0.07 points); p = 0.117) With HCQ, the most commonly reported adverse effect was related to gastrointestinal symptoms: |
